344 related articles for article (PubMed ID: 15711182)
1. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells.
Lemaire M; Momparler LF; Farinha NJ; Bernstein M; Momparler RL
Leuk Lymphoma; 2004 Jan; 45(1):147-54. PubMed ID: 15061212
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
Lemaire M; Momparler LF; Raynal NJ; Bernstein ML; Momparler RL
Cancer Chemother Pharmacol; 2009 Feb; 63(3):411-6. PubMed ID: 18398609
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
Momparler RL; Momparler LF; Samson J
Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417
[TBL] [Abstract][Full Text] [Related]
5. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
6. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
Raynal NJ; Momparler LF; Rivard GE; Momparler RL
Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
10. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
Momparler RL; Momparler LF; Samson J
Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia.
Raynal NJ; Charbonneau M; Momparler LF; Momparler RL
Oncol Res; 2008; 17(5):223-30. PubMed ID: 18980019
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Oncol; 2005 Oct; 32(5):443-51. PubMed ID: 16210084
[TBL] [Abstract][Full Text] [Related]
13. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
Momparler RL; Laliberté J
Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
[TBL] [Abstract][Full Text] [Related]
14. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
Momparler RL; Doré BT; Labiberté J; Momparler LF
Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351
[TBL] [Abstract][Full Text] [Related]
15. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA methylation and reactivation of silenced genes by zebularine.
Cheng JC; Matsen CB; Gonzales FA; Ye W; Greer S; Marquez VE; Jones PA; Selker EU
J Natl Cancer Inst; 2003 Mar; 95(5):399-409. PubMed ID: 12618505
[TBL] [Abstract][Full Text] [Related]
17. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
Momparler RL; Idaghdour Y; Marquez VE; Momparler LF
Leuk Res; 2012 Aug; 36(8):1049-54. PubMed ID: 22472464
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action.
Wilson VL; Jones PA; Momparler RL
Cancer Res; 1983 Aug; 43(8):3493-6. PubMed ID: 6190553
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
